DDInter740 DDInter1925
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Flecainide {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Flecainide {u} (Compound) upregulates {v} (Gene) GARS
GARS {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Flecainide {u} (Compound) downregulates {v} (Gene) RRM2
RRM2 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Flecainide {u} (Compound) causes {v} (Side Effect) Eye disorder
Eye disorder {u} (Side Effect) is caused by {v} (Compound) Vemurafenib
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Flecainide {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Flecainide {u} (Compound) upregulates {v} (Gene) GARS
GARS {u} (Gene) regulates {v} (Gene) PYCR1
PYCR1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Flecainide {u} (Compound) upregulates {v} (Gene) AARS
AARS {u} (Gene) is regulated by {v} (Gene) TP53
TP53 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Flecainide {u} (Compound) upregulates {v} (Gene) EIF4EBP1
EIF4EBP1 {u} (Gene) is upregulated by {v} (Disease) melanoma
melanoma {u} (Disease) is treated by {v} (Compound) Vemurafenib
Flecainide {u} (Compound) upregulates {v} (Gene) PHGDH
PHGDH {u} (Gene) is associated with {v} (Disease) melanoma
melanoma {u} (Disease) is treated by {v} (Compound) Vemurafenib
Flecainide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Vemurafenib (Compound)
Flecainide (Compound) upregulates GARS (Gene) and GARS (Gene) is upregulated by Vemurafenib (Compound)
Flecainide (Compound) downregulates RRM2 (Gene) and RRM2 (Gene) is downregulated by Vemurafenib (Compound)
Flecainide (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib (Compound)
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may lead to a major life threatening interaction when taken with Vemurafenib
Flecainide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound)
Flecainide (Compound) upregulates GARS (Gene) and GARS (Gene) regulates PYCR1 (Gene) and PYCR1 (Gene) is upregulated by Vemurafenib (Compound)
Flecainide (Compound) upregulates AARS (Gene) and AARS (Gene) is regulated by TP53 (Gene) and TP53 (Gene) is upregulated by Vemurafenib (Compound)
Flecainide (Compound) upregulates EIF4EBP1 (Gene) and EIF4EBP1 (Gene) is upregulated by melanoma (Disease) and melanoma (Disease) is treated by Vemurafenib (Compound)
Flecainide (Compound) upregulates PHGDH (Gene) and PHGDH (Gene) is associated with melanoma (Disease) and melanoma (Disease) is treated by Vemurafenib (Compound)